MCB
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
MCB Accepts, published online ahead of print on 11 December 2006
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
MCB.00882-06v1
27/4/1280    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grégoire, S.
Right arrow Articles by Yang, X.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grégoire, S.
Right arrow Articles by Yang, X.-J.

 Previous Article  |  Next Article 

Mol. Cell. Biol. doi:10.1128/MCB.00882-06
Copyright (c) 2006, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Histone deacetylase 3 interacts with and deacetylates MEF2 transcription factors

Serge Grégoire, Lin Xiao, Jianyun Nie, Xiaohong Zhang, Minghong Xu, Jiarong Li, Jieming Wong, Edward Seto, and Xiang-Jiao Yang*

Molecular Oncology Group, Department of Medicine, McGill University Health Centre, Montréal, Quebec H3A 1A1, Canada; H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida 33612; and Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030

* To whom correspondence should be addressed. Email: xiang-jiao.yang{at}mcgill.ca.


   Abstract

The myocyte enhancer factor 2 (MEF2) family of transcription factors is not only important for controlling gene expression in normal cellular programs like muscle differentiation, T cell apoptosis, neuronal survival, and synaptic differentiation, but has also been linked to cardiac hypertrophy and other pathological conditions. Lysine acetylation has been shown to modulate MEF2 function, but it is not so clear which deacetylase(s) is involved. We report here that treatment of HEK293 cells with trichostatin A or nicotinamide upregulated MEF2D acetylation, suggesting that different deacetylases catalyze the deacetylation. Related to the trichostatin A sensitivity, histone deacetylase 4 (HDAC4) and HDAC5, two known partners of MEF2, exhibited little deacetylase activity towards MEF2D. By contrast, HDAC3 efficiently deacetylated MEF2D in vitro and in vivo. This was specific since HDAC1, HDAC2 and HDAC8 failed to do so. While HDAC4, HDAC5, HDAC7 and HDAC9 are known to recognize primarily the MEF2-specific domain, we found that HDAC3 interacts directly with the MADS box. In addition, HDAC3 associated with the acetyltransferases p300 and PCAF to reverse autoacetylation. Furthermore, the nuclear receptor corepressor SMRT stimulated the deacetylase activity of HDAC3 towards MEF2 and PCAF. Supporting the physical interaction and deacetylase activity, HDAC3 repressed MEF2-dependent transcription and inhibited myogenesis. These results reveal an unexpected role for HDAC3 and suggest a novel pathway through which MEF2 activity is controlled in vivo.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2006 by the American Society for Microbiology. All rights reserved.